Application of MnO2/CS@5-ALA nanocomplex conjugated Methotrexate in magnetic resonance imaging and Radiotherapy of glioblastoma multiform (GBM) tumor cells

Abstract

Targeted drug delivery using manganese-based nanoparticles (MnO2 NPs) is an excellent option for cancer management due to its site specificity, high encapsulation capacity, and biosafety compared to conventional drug delivery systems. We used methotrexate (MTX) functionalized, 5-aminolevulinic acid (5-ALA) modified chitosan-coated manganese dioxide (MnO2/CS) NPs (i.e., MnO2/CS@5-ALA-MTX NPs) in We used magnetic resonance molecular imaging and radiation therapy of glioblastoma multiforme cells. The effect of synthesized MnO2/CS@5-ALA-MTX nanoparticles led to an increase in signal intensity in T1-weighted MR images. Still, a decrease in signal intensity in T*2- The average size, zeta potential, and multiple dispersion of MnO2/CS@5-ALA-MTX nanoparticles was 70±9 nm, -6±2 mV and 0.240, respectively. In this system, methotrexate enables tumor targeting and improves T1-T2*weighted MnO2/5-ALA MRI. MTX-functionalized MnO2/CS NPs showed tumor-enhanced radiosensitivity in vitro. Significant tumor inhibition was observed when tumors were irradiated 24/48 hours after receiving MnO2/CS@5-ALA-MTX nanoparticles. This developed MnO2/CS@5-ALA-MTX nanoparticle system may show high potential in accurate diagnosis of folate receptor overexpressing cancers such as glioblastoma. In addition, tumor-bearing cells receiving MnO2/CS@5 -ALA-MTX NPs + X-ray irradiation experienced more effective tumor rejection than X-ray and NP groups.